Provided by Tiger Trade Technology Pte. Ltd.

Boston Scientific

50.37
+1.002.03%
Post-market: 50.900.5300+1.05%19:59 EDT
Volume:35.99M
Turnover:1.81B
Market Cap:73.00B
PE:20.41
High:50.90
Open:49.22
Low:49.01
Close:49.37
52wk High:109.50
52wk Low:42.20
Shares:1.45B
Float Shares:1.45B
Volume Ratio:2.16
T/O Rate:2.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.47
EPS(LYR):1.94
ROE:15.34%
ROA:6.19%
PB:2.93
PE(LYR):25.96

Loading ...

Movement Alert|Boston Scientific Rises 3.03% in Regular Trading, Global Restructuring Plan Disclosed Ahead of Earnings Release

Market Focus
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and The Ensign Group (ENSG)

TIPRANKS
·
Jul 28

Boston Scientific (BSX) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
Jul 28

Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Intuitive Surgical (ISRG)

TIPRANKS
·
Jul 28

Boston Scientific assumed with a Buy at UBS

TIPRANKS
·
Jul 28

Boston Scientific Unveils New Restructuring Plan, Expects Job Cuts

Reuters
·
Jul 28

Boston Scientific Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 28

Boston Scientific Launches 2026 Global Restructuring Plan

TIPRANKS
·
Jul 28

Boston Scientific Launches Global Restructuring Plan with $700 Million-$800 Million in Charges

Reuters
·
Jul 28

Boston Scientific Corp - Estimates $700 Mln-$800 Mln Pre-Tax Charges, $500 Mln Annual Pre-Tax Expense Reduction - SEC Filing

THOMSON REUTERS
·
Jul 28

Boston Scientific Corp - Company Expects Headcount Reductions from Restructuring - SEC Filing

THOMSON REUTERS
·
Jul 28

NYSE Order Imbalance 902873.0 Shares on Buy Side

THOMSON REUTERS
·
Jul 28

Boston Scientific’s FARAFLEX AFib Trial Steps Up the Pulsed Field Ablation Race

TIPRANKS
·
Jul 28

Boston Scientific Continues to See Competitive Pressures, Oppenheimer Says

MT Newswires Live
·
Jul 27

Movement Alert|Boston Scientific Rises 3.08% in Regular Trading, Pre-Earnings Optimism and Institutional Buy Ratings Support Shares

Market Focus
·
Jul 27

Boston Scientific is Maintained at Outperform by Oppenheimer

Dow Jones
·
Jul 27

Oppenheimer Trims Price Target on Boston Scientific to $85 From $90, Keeps Outperform Rating

MT Newswires Live
·
Jul 27

Inspire Medical Systems Appoints AtriCure CEO Michael Carrel to Board

Reuters
·
Jul 27

Boston Scientific price target lowered to $85 from $90 at Oppenheimer

TIPRANKS
·
Jul 27

Boston Scientific recommending some percutaneous catheters be removed, FDA says

TIPRANKS
·
Jul 25